253 related articles for article (PubMed ID: 27721330)
1. Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges.
Piper PW; Millson SH
Pharmaceuticals (Basel); 2011 Oct; 4(11):1400-1422. PubMed ID: 27721330
[TBL] [Abstract][Full Text] [Related]
2. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
Schaefer S; Svenstrup TH; Guerra B
PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
[TBL] [Abstract][Full Text] [Related]
4. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
5. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
6. Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's Diseases.
Alam Q; Alam MZ; Sait KHW; Anfinan N; Noorwali AW; Kamal MA; Khan MSA; Haque A
Curr Drug Metab; 2017; 18(9):868-876. PubMed ID: 28758577
[TBL] [Abstract][Full Text] [Related]
7. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization.
Kudryavtsev VA; Khokhlova AV; Mosina VA; Selivanova EI; Kabakov AE
PLoS One; 2017; 12(3):e0173640. PubMed ID: 28291803
[TBL] [Abstract][Full Text] [Related]
8. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
9. HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line.
Graner AN; Hellwinkel JE; Lencioni AM; Madsen HJ; Harland TA; Marchando P; Nguyen GJ; Wang M; Russell LM; Bemis LT; Anchordoquy TJ; Graner MW
Int J Hyperthermia; 2017 May; 33(3):303-317. PubMed ID: 27829290
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis.
Ozören N; El-Deiry W
Exp Cell Res; 2002 Dec; 281(2):175-81. PubMed ID: 12460647
[TBL] [Abstract][Full Text] [Related]
11. [Thermosensitization of tumor cells with inhibitors of chaperone activity and expression].
Kudriavtsev VA; Makarova IuM; Kabakav AE
Biomed Khim; 2012; 58(6):662-72. PubMed ID: 23350198
[TBL] [Abstract][Full Text] [Related]
12. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
Millson SH; Prodromou C; Piper PW
Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
14. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review).
Wang X; Chen M; Zhou J; Zhang X
Int J Oncol; 2014 Jul; 45(1):18-30. PubMed ID: 24789222
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein antagonists in early stage clinical trials for NSCLC.
Hendriks LEL; Dingemans AC
Expert Opin Investig Drugs; 2017 May; 26(5):541-550. PubMed ID: 28274158
[TBL] [Abstract][Full Text] [Related]
16. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
18. Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
Wang M; Shen A; Zhang C; Song Z; Ai J; Liu H; Sun L; Ding J; Geng M; Zhang A
J Med Chem; 2016 Jun; 59(12):5563-86. PubMed ID: 26844689
[TBL] [Abstract][Full Text] [Related]
19. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibitors as selective anticancer drugs.
Kamal A; Burrows FJ
Discov Med; 2004 Oct; 4(23):277-80. PubMed ID: 20704959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
